On Wednesday, Following U.S. Stocks were among the “Top Losers“: WisdomTree Investments, Inc (NASDAQ:WETF), Home Loan Servicing Solutions Ltd (NASDAQ:HLSS), Epizyme Inc (NASDAQ:EPZM), Hyperion Therapeutics Inc (NASDAQ:HPTX)
WisdomTree Investments, Inc (NASDAQ:WETF)’s shares dwindled -3.38%, and closed at $20.86. The stock has price to sale ratio of 15.30, however, price to book ratio is 15.01. With recent decline, the year-to-date (YTD) performance reflected a 33.08% gain below last year. During the past month the stocks gain 12.63%, bringing three-month performance to 46.90% and six-month performance to 75.44%. The mean recommendation of analysts for this stock is 1.90. (where 1=Buy, 5=Sale).
WisdomTree Investments, Inc., through its subsidiaries, operates as an exchange-traded funds (ETFs) sponsor and asset manager. It offers ETFs in equities, currency, fixed income, and alternatives asset classes. The company also licenses its indexes to third parties for proprietary products, in addition to offers a platform to promote the use of WisdomTree ETFs in 401(k) plans. It develops index using its fundamentally weighted index methodology. In addition, the company provides investment advisory services. The company was founded in 1985 and is based in New York, New York.
Home Loan Servicing Solutions Ltd (NASDAQ:HLSS), declined -3.34%, and closed at $17.93. The company holds the market capitalization of $1.32B. For the last twelve months, the stock was able to keep return on equity at 15.50%, while return on assets at 2.50%, in response to its return on investment at 3.10%. Its 20-day moving average declined -1.65%, above 50-day moving average of 11.30%, below 200-day moving average of -5.66% from the latest market price of $ 17.93. The mean recommendation of analysts for this stock is 3.00.(where 1=Buy, 5=Sale).
Home Loan Servicing Solutions, Ltd., through its subsidiaries, engages in the attainment of mortgage servicing assets. Its mortgage servicing assets comprises of servicing advances, mortgage servicing rights, rights to mortgage servicing rights, and other related assets. The company was founded in 2010 and is based in George Town, the Cayman Islands.
Epizyme Inc (NASDAQ:EPZM), dipped -3.27%, and closed at $20.44. The stock volatility for the week is 16.83%, while for the month it is 7.66%. The company has the market capitalization of $728.39M. The company holds the book value per share of 4.68, whereas cash per share is 5.51. Price to book ratio remained 4.37, while price to sale ratio is 17.02. Analysts mean recommendation for the stock is said to be 1.60 (where 1=Buy, 5=sale).
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, counting INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors.
Hyperion Therapeutics Inc (NASDAQ:HPTX), dropped -3.25%, and closed at $8.73, hitting new 52-week high of $40.96.The company has the market capitalization of $831.61M. On the other hand the stock’s volatility for the week is 7.07%, and for the month is 4.63%. The stock’s price to book ratio is $ 6.10, however price to sale ratio is $7.08. Analyst’s mean recommendation regarding this stock is 1.60. (where 1=Buy, 5=Sale).
Hyperion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat orphan diseases in the United states, Canada, and internationally. The company offers RAVICTI used as a nitrogen-binding agent for chronic administration of urea cycle disorder (UCD) in adult and pediatric patients; and BUPHENYL and AMMONAPS therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate, an active pharmaceutical ingredient in RAVICTI to treat hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
